Nilsine Partners LLC Invests $848,000 in Aflac Incorporated (NYSE:AFL)

Nilsine Partners LLC bought a new position in Aflac Incorporated (NYSE:AFL - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 9,871 shares of the financial services provider's stock, valued at approximately $848,000.

A number of other hedge funds have also bought and sold shares of AFL. Impact Partnership Wealth LLC raised its position in Aflac by 471.4% in the 3rd quarter. Impact Partnership Wealth LLC now owns 400 shares of the financial services provider's stock worth $31,000 after buying an additional 330 shares during the last quarter. Czech National Bank raised its position in Aflac by 45.2% in the 3rd quarter. Czech National Bank now owns 94,486 shares of the financial services provider's stock worth $7,252,000 after buying an additional 29,395 shares during the last quarter. Asset Management One Co. Ltd. raised its position in Aflac by 1.9% in the 3rd quarter. Asset Management One Co. Ltd. now owns 247,972 shares of the financial services provider's stock worth $19,032,000 after buying an additional 4,653 shares during the last quarter. Aaron Wealth Advisors LLC purchased a new position in Aflac in the 3rd quarter worth about $201,000. Finally, TFG Advisers LLC grew its stake in shares of Aflac by 13.3% during the 3rd quarter. TFG Advisers LLC now owns 3,286 shares of the financial services provider's stock valued at $252,000 after purchasing an additional 386 shares during the period. Hedge funds and other institutional investors own 67.44% of the company's stock.

Insiders Place Their Bets

In other news, Director Thomas J. Kenny sold 5,000 shares of the company's stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $84.62, for a total transaction of $423,100.00. Following the sale, the director now directly owns 17,920 shares of the company's stock, valued at approximately $1,516,390.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Thomas J. Kenny sold 5,000 shares of the company's stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $84.62, for a total transaction of $423,100.00. Following the sale, the director now directly owns 17,920 shares of the company's stock, valued at approximately $1,516,390.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Arthur Reginald Collins sold 3,000 shares of the company's stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $79.73, for a total value of $239,190.00. Following the sale, the director now directly owns 5,592 shares in the company, valued at $445,850.16. The disclosure for this sale can be found here. Insiders sold 46,493 shares of company stock worth $3,765,706 in the last three months. 0.90% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. StockNews.com downgraded Aflac from a "hold" rating to a "sell" rating in a research note on Wednesday, April 10th. Raymond James boosted their price target on Aflac from $83.00 to $88.00 and gave the company an "outperform" rating in a research note on Friday, February 2nd. UBS Group boosted their price target on Aflac from $80.00 to $84.00 and gave the company a "neutral" rating in a research note on Wednesday, January 10th. Piper Sandler boosted their price target on Aflac from $90.00 to $95.00 and gave the company an "overweight" rating in a research note on Friday, April 5th. Finally, Wells Fargo & Company cut their price target on Aflac from $83.00 to $81.00 and set an "equal weight" rating for the company in a research note on Thursday, April 11th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $82.15.

Aflac Price Performance

AFL stock traded down $0.12 during midday trading on Friday, hitting $83.61. The company's stock had a trading volume of 1,839,028 shares, compared to its average volume of 2,169,786. Aflac Incorporated has a 12 month low of $64.10 and a 12 month high of $86.26. The company has a quick ratio of 0.06, a current ratio of 0.06 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $48.11 billion, a price-to-earnings ratio of 10.79, a price-to-earnings-growth ratio of 2.30 and a beta of 0.91. The company has a 50 day moving average of $82.69 and a two-hundred day moving average of $81.77.

Aflac (NYSE:AFL - Get Free Report) last posted its quarterly earnings results on Thursday, February 1st. The financial services provider reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.47 by ($0.22). Aflac had a return on equity of 17.59% and a net margin of 24.92%. The business had revenue of $3.78 billion during the quarter, compared to the consensus estimate of $4.44 billion. During the same quarter in the previous year, the company earned $1.29 earnings per share. On average, analysts expect that Aflac Incorporated will post 6.41 EPS for the current year.

Aflac Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.

Want to see what other hedge funds are holding AFL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aflac Incorporated (NYSE:AFL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.